MedTrace Logo

Ceprotin Treatment Registry

NCT01127529 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2021-03-17

No results posted yet for this study

Summary

The overall objective is to collect and assess data on the treatment, safety, and treatment outcomes of subjects prescribed, receiving and participating in the Ceprotin treatment registry.

Conditions

  • Protein C Deficiency

Interventions

BIOLOGICAL

Protein C Concentrate (Human)

Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.

Sponsors & Collaborators

  • UDC Rare Bleeding and Clotting Disorders Working Group (RBDWG)

    collaborator UNKNOWN

  • American Thrombosis and Hemostasis Network

    collaborator NETWORK

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-23
Primary Completion
2015-06-22
Completion
2015-06-22

Countries

  • United States
  • Austria
  • Germany
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127529 on ClinicalTrials.gov